Brief: Lisata Therapeutics- Will Evaluate Efficacy Of Certepetide
15/04/2025 14:23
April 15 (Reuters) - Lisata Therapeutics Inc LSTA.O: LISATA THERAPEUTICS- WILL EVALUATE EFFICACY OF CERTEPETIDE, AS PAYLOAD IN CONTEXT OF CATALENT'S SMARTAG ADC DUAL-PAYLOAD TECHNOLOGY PLATFORM Source text: ID:nGNX3LQqDg Further company coverage: LSTA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Lisata Therapeutics Announces New Method Of Use Patent Granted For Certepetide In The Treatment Of Pancreatic Cancer And Other Solid Tumors
NASDAQ RESUMED AT 09:55 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
U.S. STOCKS ON THE MOVE -Expeditors International, Waters, Ameresco